AN2 Therapeutics (ANTX) vs BioAge Labs (BIOA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed BioAge Labs (BIOA) over the past year, gaining 366.1% versus a loss of 50.5%. BioAge Labs is the larger company by market cap ($196.7 million vs $192.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | BIOA |
|---|---|---|
| Share price | $5.08 | $4.28 |
| Market cap | $192.75M | $196.67M |
| 1-day change | -2.68% | -9.13% |
| YTD return | +345.61% | -67.65% |
| 1-year return | +366.06% | -50.52% |
| EPS (TTM) | $-0.91 | $-2.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.99M |
| Net income (latest FY) | $-35.17M | $-80.61M |
| Operating margin | — | -1031.46% |
| Net margin | — | -896.11% |
| 52-week high | $7.19 | $25.96 |
| 52-week low | $1.00 | $4.24 |
| Distance from 52-week high | -29.35% | -83.51% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +77.17% | +572.43% |
| Average volume | 289.29K | 740.06K |
| Shares outstanding | 37.94M | 45.95M |
| Employees | 21 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed BIOA by 416.6 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
ANTX vs BIOA FAQ
Which is bigger, AN2 Therapeutics or BioAge Labs?
BioAge Labs (BIOA) is larger, with a market capitalization of $196.67M compared with $192.75M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ANTX or BIOA?
ANTX returned +366.06% over the past 12 months, compared with -50.52% for BIOA (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and BioAge Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.